+Compare
MRNA
Stock ticker:
NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
49.75B

MRNA Price Prediction, Moderna AI Recommendations

Stock market charts, price targets, analyst ratings and a financial calendar

GET INTRADAY SIGNALS
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for MRNA with price predictions
08:00 PM EDT Jun 01, 2023

MRNA's RSI Oscillator ascends from oversold territory

The RSI Oscillator for MRNA moved out of oversold territory on May 04, 2023. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 20 similar instances when the indicator left oversold territory. In of the 20 cases the stock moved higher. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

The Momentum Indicator moved above the 0 level on May 31, 2023. You may want to consider a long position or call options on MRNA as a result. In of 66 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for MRNA just turned positive on May 22, 2023. Looking at past instances where MRNA's MACD turned positive, the stock continued to rise in of 37 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where MRNA advanced for three days, in of 261 cases, the price rose further within the following month. The odds of a continued upward trend are .

MRNA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MRNA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for MRNA entered a downward trend on May 26, 2023. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.638) is normal, around the industry mean (25.045). P/E Ratio (11.123) is within average values for comparable stocks, (123.096). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.331). Dividend Yield (0.000) settles around the average of (0.030) among similar stocks. P/S Ratio (3.628) is also within normal values, averaging (307.081).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. MRNA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MRNA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I. Advisor
published Earnings

MRNA is expected to report earnings to fall 2,047.37% to -370 cents per share on August 09

Moderna MRNA Stock Earnings Reports
Q2'23
Est.
$-3.70
Q1'23
Beat
by $1.94
Q4'22
Missed
by $1.09
Q3'22
Missed
by $0.76
Q2'22
Beat
by $0.66
The last earnings report on May 04 showed earnings per share of 18 cents, beating the estimate of -175 cents. With 2.34M shares outstanding, the current market capitalization sits at 49.75B.
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Novavax (NASDAQ:NVAX), Sorrento Therapeutics (OTC:SRNEQ).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.11B. The market cap for tickers in the group ranges from 365 to 353.84B. NONOF holds the highest valuation in this group at 353.84B. The lowest valued company is CLAZF at 365.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 2%. For the same Industry, the average monthly price growth was 40%, and the average quarterly price growth was 52%. EFTR experienced the highest price growth at 77%, while BLCM experienced the biggest fall at -61%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -2%. For the same stocks of the Industry, the average monthly volume growth was -24% and the average quarterly volume growth was -48%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 86
Price Growth Rating: 54
SMR Rating: 93
Profit Risk Rating: 94
Seasonality Score: 7 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of transformative medicines for patients

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
200 Technology Square
Phone
+1 617 714-6500
Employees
3900
Web
https://www.modernatx.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
BARK1.140.08
+7.55%
BARK
LYEL3.500.17
+5.11%
Lyell Immunopharma
LPCN4.500.19
+4.41%
Lipocine
MAIN40.320.42
+1.05%
Main Street Capital Corp
EIX66.68N/A
N/A
Edison International

MRNA and

Correlation & Price change

A.I.dvisor indicates that over the last year, MRNA has been closely correlated with BNTX. These tickers have moved in lockstep 75% of the time. This A.I.-generated data suggests there is a high statistical probability that if MRNA jumps, then BNTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MRNA
1D Price
Change %
MRNA100%
+1.55%
BNTX - MRNA
75%
Closely correlated
+3.85%
VIR - MRNA
53%
Loosely correlated
+1.49%
ARCT - MRNA
48%
Loosely correlated
-0.70%
NVAX - MRNA
46%
Loosely correlated
-1.30%
ALNY - MRNA
46%
Loosely correlated
+2.65%
More